Japanese Orphan Drugs for Neurological Conditions: What Is Available for Export

Japan’s Approved Neurological Drug Base and Its International Relevance

Japan has one of the most active rare neurological disease treatment research and approval programmes in the world. Driven by a combination of MHLW orphan drug incentives, academic medical centre research, and specialist pharmaceutical companies including Nobel Pharma and OrphanPacific, Japan has approved a number of neurological treatments that remain unlicensed or in limited supply internationally.

For specialist neurology departments, rare disease centres, and hospital pharmacies managing patients with rare neurological conditions, Japan represents a significant potential source—particularly where treatments are approved by PMDA but unavailable in the destination market.

Key Neurological Conditions with Japan-Sourced Treatment Options

Spinocerebellar Ataxia

Japan has approved taltirelin hydrate (Ceredist) for improvement of ataxia in spinocerebellar ataxia—a progressive neurological condition causing coordination and balance problems. Taltirelin is a thyrotropin-releasing hormone (TRH) analogue approved in Japan but not holding Marketing Authorisation in most other markets. It is accessed internationally through unlicensed importation frameworks.

Amyotrophic Lateral Sclerosis (ALS)

Japan was among the first countries to approve riluzole (Rilutek) for ALS, and continues to be an important source for this treatment. Additionally, Japan has approved supportive nutritional and neuroprotective agents for ALS management that are accessed internationally by specialist ALS centres.

Myasthenia Gravis

Japan has approved tacrolimus (Prograf) for generalised myasthenia gravis where post-thymectomy steroid treatment is not sufficiently effective—a specific indication not universally approved elsewhere. This makes Japanese-origin tacrolimus relevant for specialist neuromuscular disease centres managing refractory myasthenia gravis.

Progressive Myoclonus Epilepsy

Piracetam (Myocalm) is approved in Japan as combination therapy with antiepileptics for cortical myoclonus, including progressive myoclonus epilepsy syndromes. While piracetam is available in some European markets, Japanese-origin formulations may be relevant where local supply is limited or specific formulations are required.

Malignant Hyperthermia and Malignant Syndrome

Dantrolene sodium (Dantrium) is approved in Japan for malignant hyperthermia and malignant syndrome, and is distributed by OrphanPacific, one of Japan’s specialist rare disease pharmaceutical companies. It is an essential agent in anaesthesia departments managing malignant hyperthermia crises and is accessed internationally where supply is constrained.

Subacute Sclerosing Panencephalitis (SSPE)

Japan has approved combination therapy protocols for SSPE—a rare, fatal progressive neurological disorder caused by persistent measles virus infection. Interferon preparations used in this context are available in Japan and are accessed by specialist paediatric neurology centres internationally.

Regulatory Frameworks for International Access

The applicable importation framework varies by destination market:

• United Kingdom: Human Medicines Regulations 2012, Regulation 167 (Specials / unlicensed import). MHRA notification required 28 days before first importation.
• Australia: TGA Special Access Scheme (SAS Category B or C) for individual patient access to unregistered medicines.
• Singapore: HSA Special Access Route (SAR) for unregistered therapeutic products required for specific clinical needs.
• European Union: Named patient or compassionate use programmes administered by national competent authorities.

Documentation Available

• Certificate of Origin (CoO)
• Certificate of Analysis (CoA)
• Patient Information Leaflet / package insert (Japanese language)
• GDP compliance documentation
• Manufacturer GMP certificate (PIC/S-compliant)

Finding Neurological Products: J-Lex Database

J-Lex (db.tasakipharma.com) provides an English-language searchable database of Japan-approved ethical medicines. Neurology procurement teams can search by active ingredient (e.g., taltirelin, dantrolene, tacrolimus) or indication to identify available products and submit enquiries.

How TASAKI PHARMA Supports Neurology Procurement

TASAKI PHARMA is a Taiwan-based pharmaceutical trading company with GDP and PIC/S GMP-compliant operations, experienced in supplying Japan-origin neurological and rare disease pharmaceuticals to specialist centres in the UK, Australia, Singapore, and Hong Kong.

• Neurological and rare disease products available via J-Lex (db.tasakipharma.com)
• CoO, CoA, and PIL documentation upon request
• GDP-compliant cold chain logistics with temperature data loggers
• Ex Works pricing in USD, EUR, or JPY

For enquiries regarding specific neurological products, visit tasakipharma.com.